APO Research
Talk to an analyst

APO RESEARCH · REPORT

Granulocyte-Colony Stimulating Factor (G-CSF) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

31 December 2025197 pages

Choose your research edition.

Industry ResearchGranulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Granulocyte-Colony Stimulating Factor (G-CSF) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Granulocyte-Colony Stimulating Factor (G-CSF) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Granulocyte-Colony Stimulating Factor (G-CSF) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Granulocyte-Colony Stimulating Factor (G-CSF) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs include Teva, Novartis, Merck, Pfizer, Amgen, SL Pharm, North China Pharmaceutical, Kyowa Kirin and Intas, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Granulocyte-Colony Stimulating Factor (G-CSF) Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Segment by Company

Teva

Novartis

Merck

Pfizer

Amgen

SL Pharm

North China Pharmaceutical

Kyowa Kirin

Intas

Hayao Group

GenSci

Dr. Reddy

Dong-A Socio

Chugai Pharmaceutical

Amoytop

Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Segment by Type

Filgrastim

Lipefigrastim

Pefigrastim

Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Segment by Application

Oncology

Blood Disease

Other

Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs industry.

Chapter 3: Detailed analysis of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Granulocyte-Colony Stimulating Factor (G-CSF) Drugsrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Filgrastim Table 3. Key Players of Lipefigrastim Table 4. Key Players of Pefigrastim Table 4. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Oncology Table 6. Key Players of Blood Disease Table 7. Key Players of Other Table 8. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 9. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region (2021-2026) & (US$ Million) Table 10. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Region (2021-2026) Table 11. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region (2027-2032) & (US$ Million) Table 12. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Region (2027-2032) Table 13. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Trends Table 14. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Drivers Table 15. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Opportunities and Challenges Table 16. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Restraints Table 17. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Company (US$ Million) & (2021-2026) Table 18. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Company (2021-2026) Table 19. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 20. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Key Company Head Office and Area Served Table 21. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Company, Product Type & Application Table 22. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Company Establishment Date Table 23. Global Company Market Concentration Ratio (CR5 and HHI) Table 24. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 25. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2021-2026) & (US$ Million) Table 27. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2027-2032) & (US$ Million) Table 28. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Type (2021-2026) Table 29. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Type (2027-2032) Table 30. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2021-2026) & (US$ Million) Table 32. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2027-2032) & (US$ Million) Table 33. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Application (2021-2026) Table 34. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Application (2027-2032) Table 35. Teva Company Information Table 36. Teva Business Overview Table 37. Teva Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Teva Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 39. Teva Recent Development Table 40. Novartis Company Information Table 41. Novartis Business Overview Table 42. Novartis Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Novartis Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 44. Novartis Recent Development Table 45. Merck Company Information Table 46. Merck Business Overview Table 47. Merck Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Merck Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 49. Merck Recent Development Table 50. Pfizer Company Information Table 51. Pfizer Business Overview Table 52. Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 54. Pfizer Recent Development Table 55. Amgen Company Information Table 56. Amgen Business Overview Table 57. Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 59. Amgen Recent Development Table 60. SL Pharm Company Information Table 61. SL Pharm Business Overview Table 62. SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 64. SL Pharm Recent Development Table 65. North China Pharmaceutical Company Information Table 66. North China Pharmaceutical Business Overview Table 67. North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 69. North China Pharmaceutical Recent Development Table 70. Kyowa Kirin Company Information Table 71. Kyowa Kirin Business Overview Table 72. Kyowa Kirin Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Kyowa Kirin Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 74. Kyowa Kirin Recent Development Table 75. Intas Company Information Table 76. Intas Business Overview Table 77. Intas Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Intas Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 79. Intas Recent Development Table 80. Hayao Group Company Information Table 81. Hayao Group Business Overview Table 82. Hayao Group Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Hayao Group Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 84. Hayao Group Recent Development Table 85. GenSci Company Information Table 86. GenSci Business Overview Table 87. GenSci Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 88. GenSci Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 89. GenSci Recent Development Table 90. Dr. Reddy Company Information Table 91. Dr. Reddy Business Overview Table 92. Dr. Reddy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 93. Dr. Reddy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 94. Dr. Reddy Recent Development Table 95. Dong-A Socio Company Information Table 96. Dong-A Socio Business Overview Table 97. Dong-A Socio Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 98. Dong-A Socio Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 99. Dong-A Socio Recent Development Table 100. Chugai Pharmaceutical Company Information Table 101. Chugai Pharmaceutical Business Overview Table 102. Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 103. Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 104. Chugai Pharmaceutical Recent Development Table 105. Amoytop Company Information Table 106. Amoytop Business Overview Table 107. Amoytop Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 108. Amoytop Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 109. Amoytop Recent Development Table 110. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2021-2026) & (US$ Million) Table 111. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2027-2032) & (US$ Million) Table 112. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2021-2026) & (US$ Million) Table 113. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2027-2032) & (US$ Million) Table 114. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021-2026) Table 116. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2027-2032) Table 117. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2021-2026) & (US$ Million) Table 118. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2027-2032) & (US$ Million) Table 119. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2021-2026) & (US$ Million) Table 120. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2027-2032) & (US$ Million) Table 121. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021-2026) Table 123. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2027-2032) Table 124. China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2021-2026) & (US$ Million) Table 125. China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2027-2032) & (US$ Million) Table 126. China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2021-2026) & (US$ Million) Table 127. China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2027-2032) & (US$ Million) Table 128. Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2021-2026) & (US$ Million) Table 129. Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2027-2032) & (US$ Million) Table 130. Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2021-2026) & (US$ Million) Table 131. Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2027-2032) & (US$ Million) Table 132. Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 133. Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021-2026) Table 134. Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2027-2032) Table 135. South America, Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2021-2026) & (US$ Million) Table 136. South America, Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2027-2032) & (US$ Million) Table 137. South America, Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2021-2026) & (US$ Million) Table 138. South America, Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2027-2032) & (US$ Million) Table 139. South America, Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. South America, Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021-2026) Table 141. South America, Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2027-2032) Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Image Figure 2. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Type: 2025 VS 2032 Figure 4. Filgrastim Image Figure 5. Lipefigrastim Image Figure 6. Pefigrastim Image Figure 7. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 8. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Application: 2025 VS 2032 Figure 9. Oncology Image Figure 10. Blood Disease Image Figure 11. Other Image Figure 12. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 14. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Region: 2025 VS 2032 Figure 15. Years Considered Figure 16. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Players in 2025 Figure 17. Global Top 5 and 10 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Players Market Share by Revenue in 2025 Figure 18. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Type (2021-2032) Figure 21. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Application (2021-2032) Figure 23. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 24. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Type (2021-2032) Figure 25. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Application (2021-2032) Figure 26. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country (2021-2032) Figure 27. United States Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 28. Canada Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 29. Mexico Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 30. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 31. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Type (2021-2032) Figure 32. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Application (2021-2032) Figure 33. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country (2021-2032) Figure 34. Germany Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 35. France Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 36. U.K. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 37. Italy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 38. Russia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 39. Nordic Countries Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 40. China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 41. China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Type (2021-2032) Figure 42. China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Application (2021-2032) Figure 43. Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 44. Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Type (2021-2032) Figure 45. Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Application (2021-2032) Figure 46. Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country (2021-2032) Figure 47. Japan Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 48. South Korea Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 49. Taiwan Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 50. Southeast Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 51. India Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 52. Australia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Type (2021-2032) Figure 55. South America, Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Application (2021-2032) Figure 56. South America, Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country (2021-2032) Figure 57. Brazil Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 58. South Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 59. Saudi Arabia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 60. Turkey Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 61. Argentina Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 62. UAE Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 63. Egypt Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 64. Chile Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 65. Research Process Figure 66. Key Executives Interviewed

Scope & coverage.

Types
  • Filgrastim
  • Lipefigrastim
  • Pefigrastim
Applications
  • Oncology
  • Blood Disease
  • Other
Companies covered
  • Teva
  • Novartis
  • Merck
  • Pfizer
  • Amgen
  • SL Pharm
  • North China Pharmaceutical
  • Kyowa Kirin
  • Intas
  • Hayao Group
  • GenSci
  • Dr. Reddy
  • Dong-A Socio
  • Chugai Pharmaceutical
  • Amoytop

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Filgrastim
  5. 1.2.3 Lipefigrastim
  6. 1.2.4 Pefigrastim
  7. 1.3 Market Analysis by Application
  8. 1.3.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  9. 1.3.2 Oncology
  10. 1.3.3 Blood Disease
  11. 1.3.4 Other
  12. 1.4 Global Market Growth Prospects
  13. 1.5 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Growth Trends by Region
  14. 1.5.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region: 2021 VS 2025 VS 2032
  15. 1.5.2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region (2021-2026)
  16. 1.5.3 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region (2027-2032)
  17. 1.6 Assumptions and Limitations
  18. 1.7 Study Goals and Objectives
  19. 1.8 Years Considered
2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Dynamics
  1. 2.1 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Trends
  2. 2.2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Drivers
  3. 2.3 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Opportunities and Challenges
  4. 2.4 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Company (2021-2026)
  2. 3.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Key Company Head office and Area Served
  4. 3.4 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Company, Product Type & Application
  5. 3.5 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Tier 1, Tier 2, and Tier 3
4 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market by Type
  1. 4.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2021-2032)
  3. 4.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Share by Type (2021-2032)
5 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market by Application
  1. 5.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2021-2032)
  3. 5.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Teva
  2. 6.1.1 Teva Company Information
  3. 6.1.2 Teva Business Overview
  4. 6.1.3 Teva Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Teva Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  6. 6.1.5 Teva Recent Developments
  7. 6.2 Novartis
  8. 6.2.1 Novartis Company Information
  9. 6.2.2 Novartis Business Overview
  10. 6.2.3 Novartis Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Novartis Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  12. 6.2.5 Novartis Recent Developments
  13. 6.3 Merck
  14. 6.3.1 Merck Company Information
  15. 6.3.2 Merck Business Overview
  16. 6.3.3 Merck Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Merck Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  18. 6.3.5 Merck Recent Developments
  19. 6.4 Pfizer
  20. 6.4.1 Pfizer Company Information
  21. 6.4.2 Pfizer Business Overview
  22. 6.4.3 Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  24. 6.4.5 Pfizer Recent Developments
  25. 6.5 Amgen
  26. 6.5.1 Amgen Company Information
  27. 6.5.2 Amgen Business Overview
  28. 6.5.3 Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  30. 6.5.5 Amgen Recent Developments
  31. 6.6 SL Pharm
  32. 6.6.1 SL Pharm Company Information
  33. 6.6.2 SL Pharm Business Overview
  34. 6.6.3 SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  36. 6.6.5 SL Pharm Recent Developments
  37. 6.7 North China Pharmaceutical
  38. 6.7.1 North China Pharmaceutical Company Information
  39. 6.7.2 North China Pharmaceutical Business Overview
  40. 6.7.3 North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  42. 6.7.5 North China Pharmaceutical Recent Developments
  43. 6.8 Kyowa Kirin
  44. 6.8.1 Kyowa Kirin Company Information
  45. 6.8.2 Kyowa Kirin Business Overview
  46. 6.8.3 Kyowa Kirin Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Kyowa Kirin Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  48. 6.8.5 Kyowa Kirin Recent Developments
  49. 6.9 Intas
  50. 6.9.1 Intas Company Information
  51. 6.9.2 Intas Business Overview
  52. 6.9.3 Intas Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Intas Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  54. 6.9.5 Intas Recent Developments
  55. 6.10 Hayao Group
  56. 6.10.1 Hayao Group Company Information
  57. 6.10.2 Hayao Group Business Overview
  58. 6.10.3 Hayao Group Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Hayao Group Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  60. 6.10.5 Hayao Group Recent Developments
  61. 6.11 GenSci
  62. 6.11.1 GenSci Company Information
  63. 6.11.2 GenSci Business Overview
  64. 6.11.3 GenSci Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 GenSci Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  66. 6.11.5 GenSci Recent Developments
  67. 6.12 Dr. Reddy
  68. 6.12.1 Dr. Reddy Company Information
  69. 6.12.2 Dr. Reddy Business Overview
  70. 6.12.3 Dr. Reddy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Dr. Reddy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  72. 6.12.5 Dr. Reddy Recent Developments
  73. 6.13 Dong-A Socio
  74. 6.13.1 Dong-A Socio Company Information
  75. 6.13.2 Dong-A Socio Business Overview
  76. 6.13.3 Dong-A Socio Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Dong-A Socio Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  78. 6.13.5 Dong-A Socio Recent Developments
  79. 6.14 Chugai Pharmaceutical
  80. 6.14.1 Chugai Pharmaceutical Company Information
  81. 6.14.2 Chugai Pharmaceutical Business Overview
  82. 6.14.3 Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  84. 6.14.5 Chugai Pharmaceutical Recent Developments
  85. 6.15 Amoytop
  86. 6.15.1 Amoytop Company Information
  87. 6.15.2 Amoytop Business Overview
  88. 6.15.3 Amoytop Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Amoytop Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  90. 6.15.5 Amoytop Recent Developments
7 North America
  1. 7.1 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032)
  2. 7.2 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type
  3. 7.2.1 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2021-2026)
  4. 7.2.2 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2027-2032)
  5. 7.2.3 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Type (2021-2032)
  6. 7.3 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application
  7. 7.3.1 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2021-2026)
  8. 7.3.2 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2027-2032)
  9. 7.3.3 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Application (2021-2032)
  10. 7.4 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country
  11. 7.4.1 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021-2026)
  13. 7.4.3 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2027-2032)
  14. 7.4.4 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032)
  2. 8.2 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type
  3. 8.2.1 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2021-2026)
  4. 8.2.2 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2027-2032)
  5. 8.2.3 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Type (2021-2032)
  6. 8.3 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application
  7. 8.3.1 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2021-2026)
  8. 8.3.2 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2027-2032)
  9. 8.3.3 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Application (2021-2032)
  10. 8.4 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country
  11. 8.4.1 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021-2026)
  13. 8.4.3 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2027-2032)
  14. 8.4.4 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032)
  2. 9.2 China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type
  3. 9.2.1 China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2021-2026)
  4. 9.2.2 China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2027-2032)
  5. 9.2.3 China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Type (2021-2032)
  6. 9.3 China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application
  7. 9.3.1 China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2021-2026)
  8. 9.3.2 China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2027-2032)
  9. 9.3.3 China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032)
  2. 10.2 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type
  3. 10.2.1 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2021-2026)
  4. 10.2.2 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2027-2032)
  5. 10.2.3 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Type (2021-2032)
  6. 10.3 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application
  7. 10.3.1 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2021-2026)
  8. 10.3.2 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2027-2032)
  9. 10.3.3 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Application (2021-2032)
  10. 10.4 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country
  11. 10.4.1 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021-2026)
  13. 10.4.3 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2027-2032)
  14. 10.4.4 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst